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A B S T R A C T
Purpose
The incidence of hematologic malignancies during pregnancy is 0.02%. However, this ﬁgure is
increasing, as women delay conception until a later age. Systemic symptoms attributed to the
development of a hematologic cancermay overlapwith physiologic changes of pregnancy. A favorable
prognosis is contingent upon early diagnosis and treatment. Therefore, a high index of suspicion is
required by health care providers. Although timely, accurate diagnosis followed by appropriate staging
is essential and should not be delayed due to pregnancy, management guidelines are lacking due to
insufﬁcient evidence-based research. Consequently, treatment is delayed, posing signiﬁcant risks to
maternal and fetal health, and potential pregnancy termination. This report provides guidelines for
clinical management of hematologic cancers during the perinatal period, which were developed by a
multidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics spe-
cialist, a neonatologist, and experienced nurses, social workers, and psychologists.
Methods
These guidelines were developed by experts in the ﬁeld during the ﬁrst International Consensus
Meeting of Prenatal HematologicMalignancies,which took place in Leuven, Belgium, onMay 23, 2014.
Results and Conclusion
This consensus summary equips health care professionals with novel diagnostic and treatment
methodologies that aim for optimal treatment of themother, while protecting fetal and pediatric health.
J Clin Oncol 34:501-508. © 2015 by American Society of Clinical Oncology
RATIONALE AND GOALS FOR A
CONSENSUS MEETING
Although uncommon, the diagnosis of a hemato-
logic malignancy during pregnancy is a dramatic,
traumatic event for the patient, her family, and the
medical team,raising therapeutic, ethical, andsocial
dilemmas. The rarity of this event precludes pro-
spective, controlled trials; most available informa-
tion is based on retrospective cohorts, observations,
and case reports. Therefore, it is essential to incor-
porate current knowledge, expert experience, and
information on emerging medications and treat-
ment approaches to provide comprehensive guide-
lines for managing these patients.
An international consensus panel was
organized to review diagnostic and novel ther-
apeutic approaches and to integrate new infor-
mation into treatment protocols for pregnant
women with hematologic cancers. Participants
were identiﬁed based on scientiﬁc and clinical
contributions to the ﬁeld. Researchers and clini-
cians who focus on the teratogenic, obstetric, and
neonatal aspects of cancer therapy were also
approached. Each member contributed a section
that was merged into a draft, which was circulated
to all participants before the meeting in Leuven,
Belgium, on May 23, 2014. The draft was revised
based on consensus achieved during the meeting.
It was then circulated to all authors and revised
until ﬁnal consensus was reached.
GUIDELINES FOR DIAGNOSTIC PROCEDURES
INCLUDING IMAGING
Diagnosing a hematologic malignancy encom-
passes a range of techniques. Pregnancy poses
special precautions for their use.
Peripheral lymph node and bone marrow
biopsies can be performed safely. Although general
anesthesia is considered safe, when it is necessary,
the risks and beneﬁts should be weighed carefully.
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Abdominal and pelvic imaging for lymphoma staging should
rely on nonionizing magnetic resonance imaging (MRI) and
ultrasonography techniques, excluding cone-beam computed
tomography (CT).
Irradiation-related fetal toxicity seems to occur when fetal
exposure exceeds 100mSv.1 The radiation exposure associated with
chest x-rays and CT examinations is signiﬁcantly lower than the
fetotoxic threshold.2 However, pelvic and abdominal CT are
prohibited due to high fetal exposure. Fluorodeoxyglucose posi-
tron emission tomography is not recommended, because it results
in pelvic irradiation and placental transfer of [18F]ﬂuorodeoxy-
glucose, which is considered fetotoxic.3
MRI is an important diagnostic tool. Although there is no
evidence of harmful fetal effects, many regulatory bodies discourage
the use of gadolinium-based compounds during pregnancy due to
concerns regarding radiofrequency ﬁeld and acoustic damage.4
Recent reviews suggest that MRI can be performed for selected
indications.5 Gadobenate dimeglumine (MultiHance, Bracco
Pharma, Milan, Italy) and gadoterate meglumine (Dotarem, Guerbet
LLC, Bloomington, IN) are safer than gadolinium, because they are
not associated with nephrogenic systemic ﬁbrosis, although studies
evaluating their general safety are required.
Although abdominal and pelvic ultrasound are less sensitive
than MRI, they are often used as inexpensive, safe, and widely
available alternatives during pregnancy. Imaging should be used
judiciously, taking into consideration the proposed technique,
imaging ﬁeld, and gestational stage.
GUIDELINES FOR CHEMOTHERAPY
The teratogenic potential of any drug depends on the extent of
placental transfer, dose, duration and timing of exposure, and genetic
variations in maternal and fetal drug metabolism. Chemotherapy
during the ﬁrst trimester can increase the risk of spontaneous
abortion, fetal death, and major malformations by 10% to 20%.6
The embryo is extremely vulnerable to drug-related terato-
genicity during organogenesis (weeks 2 to 8 of gestation). However,
some organs and systems, including the eyes, genitalia, hematopoietic
system, and CNS, remain vulnerable throughout pregnancy.7
The fetal phase (ie, second and third trimesters) is characterized
by growth and functional maturation of already formed organs and
systems. During this phase, the impact of chemotherapy is less
predictable. Although the risk of malformation is decreased, risks
of intrauterine growth retardation, preterm delivery, and low birth
weight are increased.8 Hematopoietic suppression and subclinical
renal or cardiac dysfunction have been reported, although rarely.
A limited number of drugs are proven human teratogens and
are contraindicated during pregnancy. Older-generation alkylators
(procarbazine, busulfan, chlorambucil, and nitrogen mustard)
have high teratogenic and abortive potential; whereas anthracy-
clines and vinca alkaloids (vinblastine, vincristine) have the
lowest.9 The antimetabolites aminopterin and methotrexate are
teratogenic, whereas cytarabine has lower fetotoxic potential.
Thalidomide causes phocomelia and CNS dysmorphology at a
frequency of 15% to 100%, particularly when taken 27 to 50 days
postconception. Lenalidomide and pomalidomide, the new
immunomodulating agents, are also considered teratogenic based
on their effect on rats and on the thalidomide experience in
humans.10 Tretinoin (known as all-trans-retinoic acid [ATRA]) is
associated with cardiac, craniofacial, and neurologic malforma-
tions (retinoid embryopathy) in up to 85% of cases, if taken during
the ﬁrst trimester.9,11
The increasing use of targeted anticancer therapies has com-
plicated the choice of treatment for pregnant patients because safety
data are lacking. Incorporating these new tools during pregnancy
is questionable in some instances and contraindicated in others.
A plethora of animal studies showed increased teratogenicity
with most new drugs. The most common of these, rituximab and
the tyrosine kinase inhibitors (TKIs), are discussed in detail within
the context of their relevant diseases. Intermediate- to high-dose
corticosteroids are often used as bridging therapy, providing
symptom management for non-Hodgkin lymphoma (NHL) and
Hodgkin lymphoma (HL), especially during the ﬁrst trimester.
GUIDELINES FOR RADIOTHERAPY
Treatment of hematologic malignancies is based primarily on
chemotherapeutic and biologic agents, whereas radiotherapy is
usually used in combination with chemotherapy for HL and NHL.
The decision to administer radiotherapy in a prenatal setting is
complex. Fetal exposure may cause malformations, growth retar-
dation, and death. Long-term adverse effects, including mental
retardation, sterility, and cataracts resulting from cell death due to
irreparable DNA damage, are possible, as is childhood cancer, which
is thought to arise from incomplete repair of damaged DNA.
The preponderance and severity of these effects depend strongly
on fetal dose and gestational stage. Risks of malformation, growth
retardation, and mental retardation are highest during the embry-
onic, organogenesis, and early fetal phases. Hence, radiotherapy is
generally contraindicated during the ﬁrst 15 weeks postconception
except under rare circumstances.12 After that time, the decision
depends on individual factors, including radiation energy, modality
and volume, proximity to the fetus, and treatment technique. It must
be considered that even at later stages, exposure to doses$ 100 mSv
(especially $ 500 mSv) is associated with increased risks of mal-
formation and mental retardation. After 25 weeks, # 1 Sv (1000
mSv) is considered relatively safe, depending on the radiation site.13
The probability of childhood cancer is dose dependent,
regardless of gestational stage at exposure. A dose of 100 mSv
generates a 1% increase in cancer incidence in a population.14,15
A medical physicist should be consulted regarding the esti-
mated fetal dose. Current clinical planning systems are not optimal
for estimating doses outside the treatment area. Alternatives such
as Monte Carlo simulations16 or other measurements17 should be
considered.
When the estimated dose is above 100 mSv, an informed
decision to treat needs to be made with the patient, using dosimetry
analyses provided by the medical physicist. Even if the estimated
dose is low, it should be reduced as much as possible in accordance
with the ALARA (as low as reasonably acceptable) principle.
The choices of therapeutic modality and technique are
important for achieving a low incidental dose. Electron-based
treatments generate less scattered dose, but are impractical
because they are for superﬁcial targets. Photon-based treatments
502 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Lishner et al
Downloaded from ascopubs.org by Universita Degli Studi Di Milano on November 17, 2016 from 159.149.103.009
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
need to be limited to lower energies (, 10 MV) to avoid neutron
generation. Newer conformal techniques increase the dose outside
the target volume and should be used cautiously. Protons and
carbon ions promise an even lower incidental dose and could be
future modalities of choice.18
The total dose includes leakage from the head of the radiation
device and scattered radiation from the treatment room as well as
from inside the patient. The patient should have additional pro-
tection against leakage and room scatter. Protective lead aprons
should be avoided and patient-speciﬁc shielding using bridge
construction and/or tertiary shield walls should be used instead.19
In summary, irradiation is not recommended during preg-
nancy. However, use of involved ﬁeld irradiation to locations distant
from the fetus, ensuring minimal fetal exposure, is an option, taking
into consideration gestational stage and the unique clinical scenario.
MATERNAL SUPPORTIVE CARE
Chemotherapy complications include nausea, vomiting, allergic
reactions, and high risk of infections due to disease- and treatment-
induced neutropenia. Antiemetics, including D2 receptor antag-
onists (metoclopramide)20 and serotonin receptor antagonists
(ondansetron),21 are considered safe.
A review of antibiotic use during pregnancy is beyond the
scope of this paper. Generally, aminoglycosides, trimethoprim,
and tetracyclines should not be prescribed, whereas macrolides,
cephalosporins, penicillin, and metronidazole are probably safe.22
The administration of granulocyte growth factors is probably
safe, but data are limited.23 Blood and blood products can be
transfused safely.3
Pregnancy is a hypercoagulable state in which cancer and
chemotherapy administration can increase the risk of venous
thromboembolism and placental thrombosis. Low molecular
weight heparins (LMWHs), which do not cross the placenta, are
effective and can be used prophylactically and therapeutically.24
CLINICAL CHARACTERISTICS AND MANAGEMENT OF
HEMATOLOGIC MALIGNANCIES
Lymphoma
HL is the most common hematologic cancer during preg-
nancy, followed by NHL. Diagnosis is often delayed because
symptoms mimic those accompanying pregnancy (eg, shortness of
breath, fatigue, and night sweats) and imaging studies are obtained
infrequently. Chest x-ray, MRI, and ultrasonography are usually
used for investigation and disease staging.
HL
Few patients diagnosed with HL present with asymptomatic,
early stage IA/B or IIA nonmediastinal disease.25 In these cases,
treatment may be deferred until after delivery, especially if diag-
nosis is established during the third trimester.
However, most cases require early antepartum treatment.
When HL is diagnosed during the ﬁrst trimester, a regimen based on
vinblastine monotherapy followed by classic ABVD (doxorubicin,
bleomycin, vinblastine, dacarbazine) therapy postpartum, or in case
of progression, has been used.26 However, this approach has not
been validated by other groups.27 The limited data available suggest
that ABVD may be administered safely and effectively during the
latter phases of pregnancy. Although it may be associated with
prematurity and lower birth weights, studies have not reported
signiﬁcant disadvantages.25,28
Nonpregnant patients with advanced-stage HL (stage IIB, III,
or IV) are typically treated with extended courses of multiagent
chemotherapy (ABVD or BEACOPP [bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and
prednisone]), with or without involved-ﬁeld radiotherapy.29 As in
early stage HL, ABVD can be given during the second and third
trimesters. Information about the use of BEACOPP during
pregnancy is not available. However, given the higher dose of
anthracyclines and the inclusion of alkylating agents in this reg-
imen, it should be avoided. Also, caution is advised regarding use of
supplemental oxygen if bleomycin has been administered. Bren-
tuximab vedotin administered during organogenesis caused
embryofetal lethality and teratogenicity in animals; consequently,
the product was assigned Pregnancy Category D (ADCETRIS
package insert; Takeda Italia, Cerano, Italy).
The prognosis for women diagnosed with HL during preg-
nancy seems excellent. They have similar long-term survival compared
with matched, nonpregnant controls.30
NHL
The evaluation and management of NHL during pregnancy is
complex, partly due to the pathologic and clinical heterogeneity of
the disease. Important considerations include establishing a his-
tologic diagnosis, appropriate staging with assessment of tumor
burden, type and timing of therapy, and timing of delivery.31,32
Identifying the histologic subtype is an important initial step.25
A recent, retrospective series described characteristics and outcomes
of 50 patients with NHL during pregnancy.25 The most common
subtype was diffuse large B-cell lymphoma, constituting 73% of
B-cell NHLs and 56% of all NHLs. Notably, 20% of patients had
T-cell lymphoma, all of which were peripheral/mature T-cell NHLs.
Despite suboptimal staging (eg, absence of functional imaging
such as positron emission tomography), studies of NHL during
pregnancy have shown a high incidence of extranodal involvement.33-35
Moreover, atypical extranodal sites (vagina, breast, and ovary) are
often encountered.35
Table 1 summarizes the recommended management of NHL
during pregnancy. The decision to administer antenatal therapy
is based on several factors, such as type of NHL (indolent v
aggressive), gestational age, and patient preference. Asymptomatic
patients with low tumor burden, indolent NHL may be observed,
whereas aggressive subtypes warrant systemic therapy in most
patients. However, labor should not be induced to expedite che-
motherapy. An overarching goal in the care of all pregnant patients
with NHL is delivery at term.36 Combination chemotherapy,
although relatively safe during the second and third trimesters,37,38
is contraindicated in early gestational stages.
NHLs warranting antimetabolite therapy (primary CNS lym-
phoma and Burkitt’s lymphoma) are challenging.39,40 Aggressive
chemotherapy regimens including antimetabolites during preg-
nancy have been reported. However, caution is advised regarding
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fetal teratogenicity (methotrexate [MTX] syndrome and myelo-
suppression41). Hence, they are not recommended, especially before
week 20 of gestation.
Rituximab, an IG1 k monoclonal antibody, is a backbone of
B-cell NHL treatment. It crosses the placenta via a speciﬁc, receptor-
mediated mechanism. Recent studies suggest transplacental passage
increases with gestational age. A retrospective, observational study
reported a 58% (90/153) live birth rate after rituximab exposure in
utero.42 The ﬁrst trimester miscarriage rate was 21%; most occurred
when chemotherapy was coadministered. Twenty-two (24%) infants
were born prematurely; 11 of them had transient neutropenia,
thrombocytopenia, or B-cell depletion at birth (not clinically sig-
niﬁcant). Two infants had congenital anomalies (one clubfoot and
one cardiacmalformation), suggesting that rituximab is not obviously
associated with increased incidence of malformation or infection.
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) occurs in approximately 1
of 100,000 pregnancies.43 It is often diagnosed during routine
blood testing when the patient is completely asymptomatic. Weight
loss, abdominal bloating, and night sweats, which are character-
istics of CML, can also be attributed to pregnancy. The diagnosis
can be conﬁrmed by the presence of the t(9;22) cytogenetic
abnormality and/or the fusion oncogene, BCR-ABL1; both can be
detected using bone marrow and blood samples.
The introduction of TKIs into clinical practice has changed
the outcome of CML dramatically. Approximately 90% of patients
can expect to have signiﬁcant, long-lasting responses and tolerate
at least one of the ﬁve available TKIs. Unfortunately, TKIs are
contraindicated during pregnancy. TKIs inhibit BCR-ABL1,
together with several other tyrosine kinases including c-kit, the
platelet-derived growth factor receptors a and b, arg, c-fms, and in
the case of dasatinib and bosutinib, Src and Src-related kinases.
Some of these proteins, particularly platelet-derived growth factor
receptor a, are important for embryonic implantation, gonadal
development, and fetal maturation and should thus be avoided.44
A survey of 180 fetuses exposed to imatinib (57% during
organogenesis) identiﬁed a higher than expected incidence of
skeletal malformations (eg, premature closure of skull sutures,
craniosynostosis, absent hemivertebrae, shoulder anomalies, and
scoliosis), as well as renal (eg, duplex kidney, agenesis), respiratory
(eg, hypoplastic lungs), and gastrointestinal (eg, exomphalos,
omphalocele) abnormalities.45 Exomphalos was almost 1,000-fold
higher than expected. Most women had discontinued imatinib
when or soon after pregnancy was conﬁrmed, which suggests that
the effects of TKIs occur during the ﬁrst trimester. Nevertheless,
almost 70% of pregnancies that were not electively terminated
resulted in the delivery of normal, healthy infants. Some physicians
treat pregnant CML patients from the second trimester,46 resulting
in a lower risk of malformations, although this is not recom-
mended by the drug manufacturers.
Because CMLmight have been diagnosed later had the patient
not been under maternity care, treatment may not be needed until
the white count and/or platelet count have risen to levels associated
with the onset of symptoms. An approximate guideline is white cell
count greater than 100 3 109/L and platelet count greater than
500 3 109/L. Therapeutic approaches other than TKIs should be
considered, including leukapheresis and interferon-a (IFN-a).
Leukapheresis can be effective in decreasing cell counts; however, it
is frequently required two to three times per week during the ﬁrst
and second trimesters. Counts tend to drop during the third
trimester, allowing less frequent intervention.46
IFN-a does not inhibit DNA synthesis and is considered safe in
pregnancy, based on animal studies and case reports.47-49 IFN-a is a
high molecular weight molecule and should not cross the placenta. It
should be remembered that when IFN-a was ﬁrst-line therapy for
CML, it did not always induce good hematologic control and was
often supplemented with hydroxycarbamide, a cytotoxic agent that
inhibits RNA synthesis. It is known to cause embryotoxicity, including
craniofacial and spinal defects, in many animal species,50 but seems
to be less damaging than expected in humans. In a series of ﬁve
pregnancies in which hydroxycarbamide was continued throughout
gestation, four infants were unaffected and one pregnancy resulted in
the stillbirth of a morphologically normal fetus at 26 weeks.51
Consideration should be given to adding aspirin and/or LMWH
when the platelet count is. 10003 109/L, due to increased risk for
Table 1. Therapeutic Approach in Women Diagnosed With Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Hematologic Malignancy Stage of Pregnancy* Suggested Approach
Indolent non-Hodgkin lymphoma (eg, FL) Early and late Watchful waiting.
Treat if symptomatic and/or evidence of disease progression,
using monoclonal antibodies with or without chemotherapy.
Steroids can be administered during the ﬁrst trimester as a
bridge to the second trimester, when chemotherapy can be
used with relatively greater safety.
Aggressive lymphomas Early Pregnancy termination and administration of therapy.
Late Treat as nonpregnant woman, including monoclonal antibodies
(R-CHOP).
Highly aggressive lymphoma requiring CNS prophylaxis Up to 20 weeks Pregnancy termination and administration of therapy.
After 20 weeks Adequate combination regimen including high-dose
methotrexate.
Hodgkin lymphoma Early Postpone treatment to second trimester, if possible. If not
possible, pregnancy termination and administration of
therapy.
Late Treat as nonpregnant woman.
Abbreviations: FL, follicular lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
*Early, ﬁrst trimester; late, second and third trimesters.
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thrombosis. The next section on myeloproliferative neoplasms con-
tains a detailed discussion on thrombotic risks and management.
For women who present in accelerated phase, the disease pace
needs to be carefully monitored and advice offered accordingly. In
cases of CML in blast crisis during early pregnancy (which remains
an aggressive phase of the disease with a poor prognosis, regardless
of TKI therapy), recommended management is similar to that of
acute leukemia.
Myeloproliferative Neoplasms
This section focuses on essential thrombocytosis (ET), poly-
cythemia vera (PV), and primary myeloﬁbrosis (PMF). The
incidence of myeloproliferative neoplasms (MPN) is six of 100,000
to 10 of 100,000 annually. Diagnosis is usually during the sixth or
seventh decade of life. However, ET, in particular, peaks in women
of reproductive age. Fifteen percent of patients with PVare younger
than 40 years of age at diagnosis.
ET is the most common MPN in women of childbearing age.
A large meta-analysis of pregnant women with ET reported a live
birth rate of 50% to 70%, ﬁrst trimester loss in 25% to 40%, late
pregnancy loss in 10%, placental abruption in 3.6%, and intra-
uterine growth restriction in 4.5%.52 Maternal morbidity is rare,
but stroke has been reported.53 Although limited, literature regard-
ing PV and PMF is concordant.54,55
Hydroxycarbamide (hydroxyurea) and anagrelide should be
stopped before conception, with an adequate wash-out period. In
the event of a clear indication for cytoreductive therapy, IFN-a
should be considered.
Box 1 lists factors that deﬁne high-risk pregnancies in women
with MPN, based upon clinical experience. Analysis of outcomes
in pregnant women with ET suggests that JAK2 V617F increases
the risk of loss.56 However, the strength of the association is not
sufﬁcient to recommend an alternative management strategy.
Management of low-risk pregnancy. Low-dose aspirin is safe
and advantageous in MPN.56,57 Unless clearly contraindicated,
aspirin (75 mg per day) should be offered throughout pregnancy.
For women with PV, venesection may be continued when tolerated
to maintain the hematocrit within the gestation-appropriate range.
Fetal ultrasound scans should be performed at 20, 26, and
34 weeks of gestation and uterine artery Doppler should be per-
formed at 20 weeks of gestation. If the mean pulsatility index
exceeds 1.4, the pregnancy may be considered high risk and
treatment and monitoring should be increased.58,59
Management of high-risk pregnancy. In high-risk pregnancies,
additional treatment includes cytoreductive therapy 6 LMWH. If
cytoreductive therapy is required, INF-a should be titrated to
maintain a platelet count of less than 400 3 109/L and hematocrit
within appropriate range.
Local protocols regarding interruption of LMWH should be
adhered to during labor, and dehydration should be avoided.Of note,
platelet count and hematocrit may increase postpartum, requiring
cytoreductive therapy. Thromboprophylaxis should be considered
6 weeks postpartum due to increased risk of thrombosis.52
Acute Leukemia
Acute leukemia, reported in one of 75,000 to one of 100,000
pregnancies,60-62 presents multiple medical and ethical challenges.
The remarkable anemia, thrombocytopenia, and neutropenia that
characterize acute myeloid and lymphoblastic leukemia and
impair maternal health and fetal development.63 Prompt treat-
ment is mandatory. Leukapheresis in the presence of clinically
signiﬁcant evidence of leukostasis can be considered, regardless of
gestational stage.63 For patients diagnosed with acute myeloid
leukemia (AML) during the ﬁrst trimester, pregnancy termination
followed by conventional induction therapy (cytarabine/anthracycline)
is recommended. Those diagnosed later can receive conventional
induction therapy, although this seems to be associated with increased
risk of fetal growth restriction and even fetal loss. Notably, neonates
rarely experience neutropenia and cardiac impairment unless exposed
to lipophilic idarubicin, which should not be used.64,65
Acute promyelocytic leukemia presents a unique scenario in
the setting of AML. It is often accompanied by disseminated
intravascular coagulation. ATRA, a backbone of acute promyelo-
cytic leukemia therapy, induces differentiation of leukemic cells,
but is highly teratogenic during the ﬁrst trimester.11,66 Therefore,
pregnancy termination is recommended before conventional
ATRA-anthracycline therapy.11 It demonstrates low teratogenicity
after the ﬁrst trimester and can be used then.66 Arsenic treatment is
highly teratogenic and prohibited throughout gestation.66
Although it presents challenges similar to those of AML,
acute lymphocytic leukemia (ALL) raises additional therapeutic
issues. It requires prophylactic CNS therapy, including MTX and
L-asparaginase, which are fetotoxic.67,68 MTX interferes with
Box 1. Criteria for High-Risk Myeloproliferative
Neoplasms During Pregnancy
Sustained rise in platelet count less than 1500 3 109/L.*
Previous venous or arterial thrombosis.
Previous occurrence of one or more hemorrhages
attributed to myeloproliferative neoplasms.*
Previous pregnancy complications:
a. Unexplained death of a morphologically normal fetus
10 weeks of gestation or older.
b. At least one premature delivery of a morphologically
normal fetus at less than 34 weeks of gestation due to:
i. Severe preeclampsia or eclampsia deﬁned according
to standard criteria.
ii. Recognized features of placental insufﬁciency.
c. Three or more unexplained consecutive miscarriages
at less than 10 weeks of gestation, without anatomic,
hormonal, or chromosomal abnormalities.
d. Otherwise unexplained intrauterine growth restriction.
e. Signiﬁcant antepartum or postpartum hemorrhage
requiring transfusion.
Abnormal uterine artery Doppler at week 20 of gestation
(mean pulsatility index . 1.4).
*Indication for interferon only, rather than interferon plus low molecular
weight heparin.
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organogenesis and is prohibited before week 20 of gestation.3,41
L-asparaginase may increase the high risk for thromboembolic
events attributed to the combination of pregnancy and malig-
nancy. Notably, TKIs, essential for patients with Philadelphia
chromosome-positive ALL, are teratogenic.45 Given these limi-
tations, women diagnosed with ALL before week 20 of gestation
should undergo termination of the pregnancy and conventional
treatment. After week 20, conventional chemotherapy can be
administered during pregnancy and TKIs postpartum.
Leukemia transfer to the fetus seems remarkably low.69 This
may be due to a highly protective placental barrier or the elimi-
nation of leukemic cells by the immune system.70
See Appendix (online only) on rare hematologic malig-
nancies, including hairy cell leukemia, multiple myeloma, and
myelodysplastic syndromes.
PERINATAL AND PEDIATRIC ASPECTS
Maternal hematologic malignancies are associated with mis-
carriages, thromboembolism, as well as impaired nutrient exchange,
blood ﬂow, and oxygen delivery in the intervillous placental spaces
due to leukemia cells. This leads to higher rates of fetal growth
restriction, premature birth, and perinatal mortality.
Cytotoxic treatment can increase perinatal risks.7,71,72 Tran-
sient neonatal myelosuppression, a rare complication, is seen after
chemotherapy or rituximab administration near term (ie, after
week 34 of gestation).73 To avoid such outcomes, a 3-week interval
between drug administration and anticipated delivery should be
planned to avoid accumulation of cytotoxins in the neonate.74
Accumulating prospective research has not found an association
between corticosteroids and increased rates of congenital anomalies.
Retrospective reports found a small absolute risk for clefting dys-
morphology.75 Synthetic corticosteroids cross the placenta in varying
amounts76 and differ signiﬁcantly in their ability to enter the fetal
circulation.77-80 Therefore, those that cross the placenta in smaller
amounts, such as prednisolone and methylprednisolone, should be
chosen. However, a dose-dependent effect has been observed and
use should be limited to the smallest effective dose for the shortest
duration. Table 2 includes a summary of these effects.
Fetal growth and morphology should be monitored with
ultrasound. The placenta should be examined for metastases, pri-
marily with leukemia and melanomas.81 Placental metastasis
necessitates disease upstaging and careful fetal monitoring. Neonates
should be assessed by a dysmorphologist and geneticist, and followed
up by a pediatrician for physical health, potential cardiotoxicity,
pediatric cancer, long-term neurodevelopment, and future fertility.
The varying results produced by studies on the potential
cardiotoxicity of anthracyclines indicate a need for additional
research. Gziri et al82 reported lower normal fractional shortening
and mildly thinner left ventricular wall, but normal ejection
fraction in children exposed prenatally. However, Avile´s and
colleagues83,84 reported normal cardiac morphology and function
in 81 children during 17 years of follow-up.
No association was found between prenatal diagnostic radi-
ation and increased rates of childhood and other cancers in more
than 2,000,000 exposed children.85,86 Exposure in early infancy has
been associated with increased risk for lymphomas (odds ratio
5.14; 95% CI 1.27 to 20.78).87 However, considering the wide CI,
these ﬁndings require replication. The beneﬁts of a timely, accurate
maternal diagnosis should be weighed against the low risk of
childhood mutagenicity.
Research on long-term neurodevelopment of children exposed
to chemotherapy is sparse, but reassuring.88 Avile´s and Neri84 found
no cognitive, neurologic, or psychologic abnormalities in 84 children
prenatally exposed to maternal chemotherapy during 18.7 years of
follow-up. Normal fertility and cognitive abilities were documented
in 12 second-generation children.84 However, a recent prospective
study found a 2.5-point decrease in IQ associated with each week
of prematurity in children exposed to chemotherapy.89 Iatrogenic
prematurity should be avoided to prevent impaired neurodevelopment.
With the possible exception of acute leukemia, delivery should be at
term, whenever possible.90
The safety of breastfeeding during chemotherapy should be
evaluated based on maternal health and medications used. The
LactMed Web site and neonatologist breastfeeding experts should
be consulted. When in doubt, breastfeeding is not advised.91
In conclusion, although hematologic malignancies in preg-
nancy are rare, they introduce clinical, social, ethical, and moral
dilemmas to the patient, their family, and physicians. The ther-
apeutic challenge is to preserve maternal health and survival without
endangering fetal well-being. Evidence-based data are scarce and
collaborative efforts are needed to increase the number of clinical
and basic research studies. A multidisciplinary team—including, at
minimum, an experienced hematologist/oncologist, a high-risk
obstetrics specialist, a neonatologist, as well as experienced nurses,
Table 2. Summary of the Effects of Corticosteroids During Pregnancy
Corticosteroid
Equivalent
Dose, mg*
Anti-Inﬂammatory
Potency†
Biologic
Half-Life, Hours
Placental
Transfer
Placental
Metabolism
Cortisone 31 0.8 8-12 Efﬁcient Extensive
Hydrocortisone 25 1 8-12 Efﬁcient Extensive
Prednisone 6 4 12-36 Efﬁcient Extensive
Prednisolone 6 4 12-36 Poor Extensive
Triamcinolone 5 5 12-36 Efﬁcient Resistant
Methylprednisolone 5 5 12-36 Poor Extensive
Betamethasone 1 25 36-72 Efﬁcient Resistant
Dexamethasone 1 25 36-72 Efﬁcient Resistant
*When compared with 1 mg of dexamethasone.
†When compared with hydrocortisone.
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social workers, and psychologists, providing close follow-up—is
critical to ensuring optimal maternal and fetal outcomes.
The International Network on Cancer, Infertility and
Pregnancy registers all cancers occurring during gestation
(www.cancerinpregnancy.org). Patient accrual is ongoing and
essential, because registration of new cases and long-term
follow-up will improve clinical knowledge and increase the
level of evidence.
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Appendix
Rare Hematologic Malignancies
Hairy cell leukemia. Hairy cell leukemia during pregnancy is extremely rare, with few cases reported (Williams JK: Am J Obstet
Gynecol 156:210-211, 1987; Alothman A, et al: Ann Intern Med 120:1048-1049, 1994; Rizack T, et al: Am J Hematol 84:830-841,
2009; Daver N, et al: Clin Lymphoma Myeloma Leuk 13:86-89, 2013). Management includes supportive measures and speciﬁc
treatments. Cladribine, the treatment of choice, is not recommended during pregnancy, because it is associated with teratogenicity
and fetal bone marrow suppression. Nevertheless, cladribine was administered in late pregnancy in one case only, without fetal
harm (Daver N, et al: Clin Lymphoma Myeloma Leuk 13:86-89, 2013). In general, interferon a (Baer MR, et al: Br J Haematol 81:
167-169, 1992) and rituximab28 are preferred for the treatment of hairy cell leukemia during pregnancy, and splenectomy may be
considered (Alothman A, et al: Ann Intern Med 120:1048-1049, 1994; Stiles GM, et al: J Perinatol 18:200-201, 1998; Adeniji BA,
et al: Case Rep Med pii:136823 2010; Bustamante A, et al: Rev Med Chil 138:1422-1426, 2010).
Multiple myeloma. The incidence of multiple myeloma during pregnancy is rare, with 32 cases reported (Cabanas-Perianes V,
et al: Hematol Oncol 2014, doi:10.1002/hon.2184). Thalidomide is a known teratogen. There is no information on bortezomib and
lenalidomide, and they are contraindicated during pregnancy.3 In contrast, corticosteroids are considered safe during pregnancy
and may be used as a bridge until administration of deﬁnitive postpartum treatment.10 For treating skeletal events such as lytic
lesions or fractures, only scant information regarding the safety of bisphosphonate use during pregnancy is available. Use of
bisphosphonates should be based on risk-beneﬁt considerations, considering the scant data regarding fetal safety (Djokanovic N,
et al: J Obstet Gynaecol Can 30:1146-1148, 2008).
Myelodysplastic syndromes. Myelodysplastic syndromes present clonal marrow stem cell disorders, characterized by ineffective
hematopoiesis and blood cytopenias, with potential progression/transformation to acute myeloid leukemia (Ade`s L, et al: Lancet
383:2239-2252, 2014). Therapeutic options in nonpregnant patients include supportive measures and hypomethylating agents.
There are no reports on the use of 5-azacitidine during pregnancy; hence it is not recommended.
Repeated platelet and erythrocyte transfusions can be safely administered (Siddiqui T, et al: Cancer 66:377-381, 1990;
Christiaens F, et al: Int J Obstet Anesth 6:270-273, 1997; Hara K, et al: Can J Anaesth 45:157-163, 1998; Steensma DP, et al: Leuk
Lymphoma 42:1229-1234, 2001; Ikeda Y, et al: Leuk Res 26:255-260, 2002; Volpicelli P, et al: Leuk Res 32:1605-1607, 2008; Gidiri M,
et al: J Obstet Gynaecol 29:665-667, 2009). In some cases, recombinant human erythropoietin was applied after the ﬁrst trimester
with no adverse fetal effects (Harris SA, et al: Obstet Gynecol 87:812-814, 1996; Sackmann Massa F, et al: Leuk Res 33:e23-e25,
2009). Nevertheless, the safety of recombinant human erythropoietin remains uncertain, and use during pregnancy should be
minimized.
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